Research has been completed on a proprietary compound called Kre-Celazine and its efficacy in treating juvenile rheumatoid/idiopathic arthritis. Jeff Golini, CEO and executive scientist at All American Pharmaceutical, developed the compound and conducted clinical research with afflicted children between the ages of seven and 16, which earned Kre-Celazine Orphan Drug Status from FDA in 2013. The research article "Kre-Celazine as a Viable Treatment for Juvenile Rheumatoid/Idiopathic Arthritis - A Pilot Study," was accepted into the Journal of Medical Food and is expected to be published later this year. Kre-Celazine is awaiting official FDA licensing for the disease indication.
Golini tentatively plans to present his arthritis research at the Federation of American Societies for Experiement biology (FASEB) during the Big Sky Montana - Nutrition Sensing and Metabolic Signaling conference later this year.
“You can expect to see more research and development coming out of All American Pharmaceutical in the coming months and years," Golini said. "Our pipeline of products is steadily increasing, as we are slowly ramping up research geared toward examining the impact of our proprietary products on various physiological conditions."